Vivesto signs agreement with CRO to evaluate anti-cancer drug formulations
pharmafile | April 22, 2022 | News story | Medical Communications |
Vivesto AB, an oncology-focused pharmaceutical company, has announced that it is advancing research into its proprietary drug delivery formulations, and has signed a research agreement with Visikol Inc.
Visikol is a leading US contract research services provider (CRO). Visikol will conduct research to evaluate the cellular effects of new and existing anti-cancer drug formulations, developed using Vivesto’s proprietary XR-17 and XR-18 technologies.
Reinhard Koenig, MD, CSO of Vivesto, commented: “We continue to advance our internal research efforts by developing our XR-17™ and XR-18 technologies, including line extensions and formulations with anti-cancer compounds. We are working hard to achieve a deeper understanding of the cellular effects of these formulations and have therefore partnered with Visikol, an experienced U.S. services company, to provide valuable insights. We are looking forward to integrating the output of this research into the development of new compounds.”
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets, targeting late-stage cancers.
As a result of the research, Vivesto will be able to assess anti-cancer compounds formulated with its XR-17 drug delivery platform, as well as line extensions formulated with the XR-18 technology that it is currently developing, examining their therapeutic properties and underlying biologic effects.
The research will allow Vivesto to select promising developmental drug candidates and further expand its current and future oncology pipeline, focused on hard-to-treat and late-stage cancers.
Visikol specialises in accelerating the drug discovery and development process, and provides advanced tissue imaging and cell culture services.
Ana Ovey
